SCHEMBL5741290

SCHEMBL5741290

C=Cc1ccc(S(=O)(=O)N2CCN(CC3(NC(=O)OCCC)CCN(c4ccncc4)CC3)C(=O)C2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C19 P33261 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37
HIF1A Q16665 1/20 0.37
SPHK1 Q9NYA1 2/20 0.35
F10 P00742 3/20 0.35
ATM Q13315 1/20 0.34
ITGB3 P05106 3/20 0.34
ITGA2B P08514 3/20 0.34
NPSR1 Q6W5P4 1/20 0.34
LMNA P02545 1/20 0.34
MMP2 P08253 1/20 0.33
MMP13 P45452 1/20 0.33
ADAM17 P78536 1/20 0.33
TSHR P16473 1/20 0.33
LSS P48449 1/20 0.33
F13A1 P00488 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5740527 0.94 ATM (0.39) CYP1A2CYP2D6CYP2C19SMN1; SMN2CYP3A4
SCHEMBL5740189 0.92 SMN1; SMN2 (0.39) CYP1A2CYP2D6CYP2C19SMN1; SMN2CYP3A4
SCHEMBL5741473 0.88 ITGB3 (0.34) CYP1A2CYP2D6CYP2C19SMN1; SMN2CYP3A4
SCHEMBL5740518 0.86 ATM (0.36) F10ATMNPSR1LMNATSHR
SCHEMBL5741976 0.85 ATM (0.37) SMN1; SMN2F10ATMNPSR1LMNA
Hydrochloric Acid SCHEMBL5742036 0.85 ATM (0.36) SMN1; SMN2F10ATMNPSR1LMNA
SCHEMBL5740885 0.85 F10 (0.52) F10
SCHEMBL5742755 0.84 LSS (0.44) CYP1A2CYP2D6CYP2C19SMN1; SMN2CYP3A4
SCHEMBL5743483 0.84 ATM (0.36) SMN1; SMN2F10ATMNPSR1LMNA
SCHEMBL5740503 0.81 CYP2D6 (0.34) CYP1A2CYP2D6CYP2C19SMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109200-B2 Carbamate derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-09-19 US claimed
EP-1340753-B1 CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2006-01-11 EP claimed
US-20040038986-A1 Carbamate derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-26 US claimed
EP-1340753-A1 CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP claimed
US-7109200-B2 Carbamate derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-09-19 US disclosed
US-20040038986-A1 Carbamate derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-26 US disclosed
EP-1340753-A1 CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038986-A1 Carbamate derivatives, process for producing the same and use thereof CFH, F11, F2 CYP1A2 83/4885CYP2D6 251/4885CYP2C19 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.